Cargando…

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

BACKGROUND: Synapse damage and loss are fundamental to the pathophysiology of Alzheimer’s disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical development approaches for AD therapeutics that can demonstrate reduction of syn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colom-Cadena, Martí, Spires-Jones, Tara, Zetterberg, Henrik, Blennow, Kaj, Caggiano, Anthony, DeKosky, Steven T., Fillit, Howard, Harrison, John E., Schneider, Lon S., Scheltens, Phillip, de Haan, Willem, Grundman, Michael, van Dyck, Christopher H., Izzo, Nicholas J., Catalano, Susan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053087/ https://www.ncbi.nlm.nih.gov/pubmed/32122400 http://dx.doi.org/10.1186/s13195-020-00588-4

Ejemplares similares

A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease
por: Grundman, Michael, et al.
Publicado: (2019)

A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter
por: LaBarbera, Kelsie M., et al.
Publicado: (2023)

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification
por: Izzo, Nicholas J., et al.
Publicado: (2021)

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
por: Brinkmalm, Ann, et al.
Publicado: (2014)

Proceedings from the Fourth International Symposium on σ-2 Receptors: Role in Health and Disease
por: Izzo, Nicholas J., et al.
Publicado: (2020)

Reducing voltage-dependent potassium channel Kv3.4 levels ameliorates synapse loss in a mouse model of Alzheimer’s disease
por: Yeap, Jie, et al.
Publicado: (2022)

Alzheimer's disease: synapses gone cold
por: Koffie, Robert M, et al.
Publicado: (2011)

[18F]-T807 tauopathy PET imaging in chronic traumatic encephalopathy
por: Gandy, Sam, et al.
Publicado: (2014)

Pathology of Synapses and Dendritic Spines
por: Knafo, Shira, et al.
Publicado: (2012)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Antemortem biomarker support for a diagnosis of clinically probable chronic traumatic encephalopathy
por: Pullman, M Y, et al.
Publicado: (2017)

Association between single moderate to severe traumatic brain injury and long-term tauopathy in humans and preclinical animal models: a systematic narrative review of the literature
por: Walker, Ariel, et al.
Publicado: (2022)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Apolipoprotein E isoform does not influence trans-synaptic spread of tau pathology in a mouse model
por: Davies, Caitlin, et al.
Publicado: (2023)

Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases
por: Lizama, Britney N., et al.
Publicado: (2023)

Avoiding Death by Meeting: An Interactive Workshop for Academic Faculty Highlighting Strategies to Facilitate Effective Team Meetings
por: Merriam, Sarah, et al.
Publicado: (2021)

Neurofilaments in blood is a new promising preclinical biomarker for the screening of natural scrapie in sheep
por: Zetterberg, Henrik, et al.
Publicado: (2019)

Clusterin accumulates in synapses in Alzheimer’s disease and is increased in apolipoprotein E4 carriers
por: Jackson, Rosemary J, et al.
Publicado: (2019)

The Calcium-Binding Protein EFhd2 Modulates Synapse Formation In Vitro and Is Linked to Human Dementia
por: Borger, Eva, et al.
Publicado: (2014)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
por: Vaisman-Mentesh, Anna, et al.
Publicado: (2020)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Regional Brain Volumes Associated With Depression in the National Alzheimer’s Coordinating Center Uniform Data Set
por: Burke, Shanna, et al.
Publicado: (2020)

The Effect of Anxiety on Regional Brain Volumes in the National Alzheimer’s Coordinating Center Uniform Data Set
por: Burke, Shanna, et al.
Publicado: (2020)

The Impact of Sleep Disturbance on Regional Brain Volumes
por: Burke, Shanna, et al.
Publicado: (2020)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Fluid biomarkers in Alzheimer’s disease – current concepts
por: Rosén, Christoffer, et al.
Publicado: (2013)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men
por: Benedict, Christian, et al.
Publicado: (2020)

Extracellular fluid, cerebrospinal fluid and plasma biomarkers of axonal and neuronal injury following intracerebral hemorrhage
por: Tobieson, Lovisa, et al.
Publicado: (2021)

Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data
por: Kocis, Petr, et al.
Publicado: (2017)

Lifestyle Complexity and Dementia Risk: Examining Moderation by APOE Genotype and Mild Cognitive Impairment
por: Moored, Kyle, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i7jhvus4ca626uht1k73u2mdj8